EARNINGS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2023

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:


	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022
Stock option awards	1,345,914	900,378	1,111,271	836,957
Restricted stock awards	48,690	136,568	591,176	389,831
Performance stock unit awards	—	—	152,189	—

Schedule of Basic and Diluted Earnings Per Share

The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Numerator:
Net income (1)	$	114,403	$	33,929	$	153,611	$	64,204
Denominator:
Weighted average number of common shares outstanding	179,807		180,621		180,531		180,293
Earnings per common share:
Earnings per common share, basic	$	0.64	$	0.19	$	0.85	$	0.36

(1) Net income for the three and six months ended June 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, Business Combinations, for further discussion.

The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Numerator:
Net income (1)	$	114,403	$	33,929	$	153,611	$	64,204
Denominator:
Weighted average number of common shares outstanding	179,807		180,621		180,531		180,293
Effect of dilutive securities	1,434		997		1,400		883
Weighted average number of common shares outstanding, diluted	181,241		181,618		181,931		181,176
Earnings per common share:
Earnings per common share, diluted	$	0.63	$	0.19	$	0.84	$	0.35